Volkov Ilia, Rudoy Inna, Freud Tamar, Sardal Gabriel, Naimer Sody, Peleg Roni, Press Yan
Department of Family Medicine, Ben-Gurion University of the Negev Beer-Sheva, Israel.
J Am Board Fam Med. 2009 Jan-Feb;22(1):9-16. doi: 10.3122/jabfm.2009.01.080113.
The frequency of recurrent aphthous stomatitis (RAS), the most common oral mucosa lesions seen in primary care, is up to 25% in the general population. However, there has been no optimal therapeutic approach. Our objective was to confirm our previous clinical observation of the beneficial treatment of RAS with vitamin B(12).
A randomized, double-blind, placebo-controlled trial was done using primary care patients. A sublingual a dose of 1000 mcg of vitamin B(12) was used in patients in the intervention group for 6 months.
In total, 58 patients suffering from RAS participated in the study: 31 were included in the intervention group and 27 were included in control group. All parameters of RAS among patients in the intervention group were recorded and compared with the control group. The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood. During the last month of treatment a significant number of participants in the intervention group reached "no aphthous ulcers status" (74.1% vs 32.0%; P < .01).
Vitamin B(12) treatment, which is simple, inexpensive, and low-risk, seems to be effective for patients suffering from RAS, regardless of the serum vitamin B(12) level.
复发性阿弗他口炎(RAS)是基层医疗中最常见的口腔黏膜病变,在普通人群中的发病率高达25%。然而,目前尚无最佳治疗方法。我们的目的是证实我们之前关于维生素B12对RAS有有益治疗效果的临床观察。
对基层医疗患者进行了一项随机、双盲、安慰剂对照试验。干预组患者舌下含服1000微克维生素B12,为期6个月。
共有58例RAS患者参与研究:31例纳入干预组,27例纳入对照组。记录干预组患者RAS的所有参数,并与对照组进行比较。无论血液中初始维生素B12水平如何,在使用维生素B12治疗的第5和6个月,发作持续时间、溃疡数量和疼痛程度均显著降低(P < .05)。在治疗的最后一个月,干预组中有相当数量的参与者达到了“无阿弗他溃疡状态”(74.1%对32.0%;P < .01)。
维生素B12治疗简单、廉价且风险低,似乎对RAS患者有效,无论血清维生素B12水平如何。